We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 06, 2020

Pathological Response in Patients With Large Unresected Intermediate- or High-Grade Soft Tissue Sarcoma Receiving Preoperative Chemoradiotherapy ± Pazopanib

The Lancet Oncology


Additional Info

The Lancet Oncology
Pathological Response in Children and Adults With Large Unresected Intermediate-Grade or High-Grade Soft Tissue Sarcoma Receiving Preoperative Chemoradiotherapy With or Without Pazopanib (ARST1321): A Multicentre, Randomised, Open-Label, Phase 2 Trial
Lancet Oncol 2020 Jul 20;[EPub Ahead of Print], AR Weiss, YL Chen, TJ Scharschmidt, YY Chi, J Tian, JO Black, JL Davis, JC Fanburg-Smith, E Zambrano, J Anderson, R Arens, O Binitie, E Choy, JW Davis, A Hayes-Jordan, SC Kao, ML Kayton, S Kessel, R Lim, WH Meyer, L Million, SH Okuno, A Ostrenga, MT Parisi, DA Pryma, RL Randall, MA Rosen, M Schlapkohl, BL Shulkin, EA Smith, JI Sorger, S Terezakis, DS Hawkins, SL Spunt, D Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading